Business Summary: Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Guerbet SA revenues increased 7% to EUR841.1M. Net income applicable to common stockholders decreased 33% to EUR16.1M. Revenues reflect X-rays segment increase of 10% to EUR478.6M, Interventional Radiology and Theranostics (RIT) segment increase of 7% to EUR100.1M, World excl. Europe segment increase of 14% to EUR493.7M.